Azacitidine was generally well tolerated in patients ≥ 75 years of age in QUAZAR AML-001
A subgroup analysis from QUAZAR AML-001 presented at EHA 2021 shows that maintenance treatment with azacitidine was generally well tolerated in all age groups, including elderly (≥75 years) AML patients. Also, the study shows improvement in survival by 14.9 months compared with placebo and in progression-free survival by 7.9 months for this group of patients.
